Giancarlo Pruneri

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 19

Top Topics

Breast Cancer Cells

Systemic Lupus Erythematosus

Top Venues

Cancer discovery

NPJ breast cancer

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Iros Barozzi, Neil Slaven, Eleonora Canale, Rui Lopes, Inês A M Barbosa, Melusine Bleu, Diana Ivanoiu, Claudia Pacini, Emanuela Mensa, Alfie Chambers, Sara Bravaccini, Sara Ravaioli, Gyorffy Balazs, Maria Vittoria Dieci, Giancarlo Pruneri, Giorgio Giacomo Galli, Luca Magnani
A functional survey of the regulatory landscape of estrogen-receptor-positive breast cancer evolution. Cancer discovery (2024)
Dalia Rosano, Emre Sofyali, Heena Dhiman, Chiara Ghirardi, Diana Ivanoiu, Timon Heide, Andrea Vingiani, Alessia Bertolotti, Giancarlo Pruneri, Eleonora Canale, Hannah F Dewhurst, Debjani Saha, Neil Slaven, Iros Barozzi, Tong Li, Grigory Zemlyanskiy, Henry Phillips, Chela James, Gyorffy Balazs, Claire Lynn, George D Cresswell, Farah Rehman, Roberta Noberini, Tiziana Bonaldi, Andrea Sottoriva, Luca Magnani
Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells. Cancer discovery 14 (5) (2024)
Dalia Rosano, Emre Sofyali, Heena Dhiman, Chiara Ghirardi, Diana Ivanoiu, Timon Heide, Andrea Vingiani, Alessia Bertolotti, Giancarlo Pruneri, Eleonora Canale, Hannah F Dewhurst, Debjani Saha, Neil Slaven, Iros Barozzi, Tong Li, Grigory Zemlyanskiy, Henry Phillips, Chela James, Gyorffy Balazs, Claire Lynn, George D Cresswell, Farah Rehman, Roberta Noberini, Tiziana Bonaldi, Andrea Sottoriva, Luca Magnani
Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells. Cancer discovery (2024)
Dalia Rosano, Emre Sofyali, Heena Dhiman, Chiara Ghirardi, Diana Ivanoiu, Timon Heide, Andrea Vingiani, Alessia Bertolotti, Giancarlo Pruneri, Eleonora Canale, Hannah F Dewhurst, Debjani Saha, Neil Slaven, Iros Barozzi, Tong Li, Grigory Zemlyanskiy, Henry Phillips, Chela James, Gyorffy Balazs, Claire Lynn, George D Cresswell, Farah Rehman, Roberta Noberini, Tiziana Bonaldi, Andrea Sottoriva, Luca Magnani
Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells. Cancer discovery 14 (5) (2024)
Dalia Rosano, Emre Sofyali, Heena Dhiman, Chiara Ghirardi, Diana Ivanoiu, Timon Heide, Andrea Vingiani, Alessia Bertolotti, Giancarlo Pruneri, Eleonora Canale, Hannah F Dewhurst, Debjani Saha, Neil Slaven, Iros Barozzi, Tong Li, Grigory Zemlyanskiy, Henry Phillips, Chela James, Gyorffy Balazs, Claire Lynn, George D Cresswell, Farah Rehman, Roberta Noberini, Tiziana Bonaldi, Andrea Sottoriva, Luca Magnani
Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells. Cancer discovery 14 (5) (2024)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 19 (1) (2023)
Giancarlo Pruneri, Daniele Lorenzini, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
The central role of pathology labs in breast cancer precision oncology: a call for action. NPJ breast cancer 9 (1) (2023)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 19 (1) (2023)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 19 (1) (2023)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 19 (1) (2023)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 19 (1) (2023)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 19 (1) (2023)
Giancarlo Pruneri, Daniele Lorenzini, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
The central role of pathology labs in breast cancer precision oncology: a call for action. NPJ breast cancer 9 (1) (2023)
Lorenzo Castagnoli, Simona Corso, Alma Franceschini, Alessandra Raimondi, Sara Erika Bellomo, Matteo Dugo, Federica Morano, Michele Prisciandaro, Silvia Brich, Antonino Belfiore, Andrea Vingiani, Maria Di Bartolomeo, Giancarlo Pruneri, Elda Tagliabue, Silvia Giordano, Filippo Pietrantonio, Serenella Maria Pupa
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer. Cellular oncology (Dordrecht) (2023)
Andrea Vingiani, Luca Agnelli, Matteo Duca, Daniele Lorenzini, Silvia Damian, Claudia Proto, Monica Niger, Federico Nichetti, Elena Tamborini, Federica Perrone, Alberta Piccolo, Siranoush Manoukian, Jacopo Azzollini, Marta Brambilla, Elena Colombo, Salvatore Lopez, Claudio Vernieri, Francesca Marra, Elena Conca, Adele Busico, Iolanda Capone, Fabio Bozzi, Marta Angelini, Andrea Devecchi, Rebecca Salvatori, Valentina De Micheli, Anna Baggi, Silvia Pasini, Claudio Jommi, Vito Ladisa, Giovanni Apolone, Filippo De Braud, Giancarlo Pruneri
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care. JCO precision oncology 7 (2023)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, Claudio Vernieri, Antonino Belfiore, Luca Agnelli, Gianpaolo Dagrada, Diana Ivanoiu, Giuseppina Bonizzi, Elisabetta Munzone, Luana Lippolis, Martina Dameri, Francesco Ravera, Marco Colleoni, Giuseppe Viale, Luca Magnani, Alberto Ballestrero, Gabriele Zoppoli, Giancarlo Pruneri
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC). PLoS genetics 19 (1) (2023)
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Curigliano Giuseppe, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. NPJ breast cancer 9 (1) (2023)
Giancarlo Pruneri, Daniele Lorenzini, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
The central role of pathology labs in breast cancer precision oncology: a call for action. NPJ breast cancer 9 (1) (2023)
Iolanda Capone, Fabio Bozzi, Gian Paolo Dagrada, Paolo Verderio, Elena Conca, Adele Busico, Maria Adele Testi, Valentina Monti, Matteo Duca, Claudia Proto, Silvia Damian, Alberta Piccolo, Federica Perrone, Elena Tamborini, Andrea Devecchi, Paola Collini, Daniele Lorenzini, Andrea Vingiani, Luca Agnelli, Giancarlo Pruneri
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples. Exploration of targeted anti-tumor therapy 3 (5) (2022)